[Hidradenitis suppurativa treated with infliximab]

An Bras Dermatol. Nov-Dec 2009;84(6):695-7. doi: 10.1590/s0365-05962009000600022.
[Article in Portuguese]

Abstract

Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies ('biological therapy'), has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Infliximab
  • Male
  • Middle Aged

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Infliximab